Under the collaboration, fqubed will expand the scope of its Tempest high throughput experimentation platform to evaluate potential formulations for its partner’s product portfolio. Tempest is currently used to screen the impact that formulation variations have on the penetration of a drug molecule through skin.
Dan Chicoine, Nuvo’s chairman, said: “The fqubed technologies have valuable applications beyond our primary focus on pharmaceutical products delivered to and through the skin.
“Collaboration agreements such as this allow us to leverage the power of our transdermal screening and high throughput formulation development platforms in complementary areas, and to improve our research capabilities so that we can more effectively develop our own topical drug pipeline.”